Suki AI

About Suki AI

Suki AI was founded in 2017 in Redwood City, California, and focuses exclusively on AI-powered clinical documentation for healthcare providers. Its flagship product, Suki Assistant, uses ambient voice AI to listen to physician-patient consultations and automatically generate structured clinical notes — SOAP notes, visit summaries, referral letters, and EHR-formatted documentation. The goal is to reduce physician documentation burden, which studies have identified as a significant contributor to clinician burnout. Suki integrates with major Electronic Health Record (EHR) systems including Epic, Cerner, Athenahealth, and Meditech, and its AI is purpose-trained on clinical language and medical terminology rather than general-purpose LLMs, resulting in higher accuracy for clinical context. The ambient AI mode — where Suki listens passively during a consultation and generates notes automatically — represents the current state of the art in clinical AI documentation. For European healthcare organisations, Suki presents significant compliance challenges that must be evaluated carefully. Patient consultation data — including voice recordings and transcriptions — constitutes special category data under GDPR Article 9. Suki is a US company with infrastructure in the United States, and there is no EU data residency option documented for European deployments. Processing special category health data on US infrastructure under US legal jurisdiction raises material GDPR Article 44 transfer concerns. Suki holds HIPAA compliance (designed for US healthcare law) and SOC 2 Type II certification. It is not ISO 27001 certified as of early 2026. While HIPAA compliance demonstrates a baseline healthcare data security posture, it does not substitute for GDPR compliance for EU patient data. For EU healthcare organisations, ambient clinical AI tools with EU data residency — or EU-native alternatives — would be a more appropriate starting point. Suki is included here as a reference for what the technology capability looks like, with the clear note that EU deployment of this specific product for patient consultation data would require extensive legal review and almost certainly a bespoke data processing arrangement with dedicated EU infrastructure.